达方吡啶改善多发性硬化相关的行走障碍
摘要
多发性硬化(multiple sclerosis,MS)是一种中枢神经系统(central nervous system,CNS)的炎性脱髓鞘性疾病,病理学特征包括血管周围炎性细胞浸润、脱髓鞘、轴索丢失和少突胶质细胞损害等.临床可表现为视觉缺失或复视、肌力减弱、感觉异常或缺失等[1] .其中行走障碍限制患者参与各种活动,是MS 最令人恐惧和致残的症状之一[2] .
出处
《中华脑科疾病与康复杂志（电子版）》
2012年第2期129-131,共3页
Chinese Journal of Brain Diseases and Rehabilitation（Electronic Edition）
参考文献24
-
1Compston A,Cole A. Mutiple Sclerosis[J].The Lancet,2008,(9648):1502-1517.
-
2Dunn J. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis[J].Expert Rev Pharmacoecon Outcomes Res,2010,(04):433-440.
-
3Shi R,Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord[J].Neuroscience,1997,(02):553-562.
-
4Wu ZZ,Chen SR,Pan HL. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit[J].Journal of Biological Chemistry,2009,(52):36453-36461.
-
5Smith W,Swan S,Marbury T. Single-dose pharmacokinetics of sustained-release fampridine (fampridine-SR) in healthy volunteers and adults with renal impairment[J].Journal of Clinical Pharmacology,2010,(02):151-159.
-
6Henney HR 3rd,Faust B,Blight AR. Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers[J].American Journal of Health-System Pharmacy,2011,(22):2148-2154.
-
7Vollmer T,Blight AR,Henney HR 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis:a 2-week,open-label,follow-up study[J].Clinical Therapeutics,2009,(10):2215-2223.
-
8Blight AR,Henney HR. Pharmacokinetics of 14 C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine)in healthy volunteers[J].Clinical Therapeutics,2009,(02):328-335.
-
9Judge SI,Lee JM,Bever CT Jr. Voltage-gated potassium channels in multiple sclerosis:Overview and new implications for treatment of central nervous system inflammation and degeneration[J].Journal of Rehabilitation Research and Development,2006,(01):111-122.
-
10Hersh C,Rae-Grant A. Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment[J].Ther Adv Neurol Disord,2012,(04):199-204.
-
1谢攀,白玉,张濛,史炎鑫.中医综合疗法治疗跟痛症临床观察[J].风湿病与关节炎,2016,5(2):17-20. 被引量：14
-
2连彦芬,王彦奎.辨证分型治疗多发性硬化体会[J].河北中医,2008,30(7):718-719. 被引量：5
-
3崔花顺,陈申旭,程玲,秦亮甫.秦氏“头八针”为主针药结合对多发性硬化患者生存质量的影响[J].中医杂志,2010,51(S2):214-215. 被引量：4
-
4郑金美.男人多运动 衰老晚来缠[J].现代养生,2015,0(3):67-68.
-
5李青,詹文涛.詹文涛教授从虚损论治多发性硬化经验[J].云南中医中药杂志,2008,29(11):1-2. 被引量：10
-
6杨春玉.清开灵注射液过敏致双下肢行走障碍1例[J].四川医学,2009,30(1):137-137. 被引量：3
-
7迪丽娜,安月莉.84例复视病因研究分析[J].新疆医学,2005,35(5):129-130. 被引量：1
-
8王健瑚.看东西双影是何病[J].家庭用药,2010(11):61-62.
-
9易维江.痛点阻滞治疗顽固性跟痛症[J].疼痛,1999,7(4):155-156.
-
10唐志坚.布鲁氏菌病的流行病学调查及分析[J].中国卫生产业,2015,12(3):7-8. 被引量：17
